Beam Therapeutics Inc (BEAM)
$26.65
+1.6
(+6.39%)▲
Beam Therapeutics Inc Key Statistics
Market Capitalization | $2.1B |
Revenue TTM | $349.6M |
EBITDA | $-160.8M |
Earnings Per Share (EPS) | $-1.58 |
Profit Margin | -41.07% |
Quarterly Earnings Growth YOY | 0.0% |
Return On Equity TTM | -18.29% |
Beam Therapeutics Inc share price movements
- $25.59$26.90$26.65
3.98%
Downside
Day's Volatility :4.87%
Upside
0.93%
- $20.84$49.50$26.65
21.8%
Downside
52 Weeks Volatility :57.9%
Upside
46.16%
Beam Therapeutics Inc Returns
| Period | Beam Therapeutics Inc | |
|---|---|---|
3 Months | -1.7% | |
6 Months | 10.03% | |
1 Year | -8.61% | |
3 Years | -66.13% |
Analyst Recommendation on Beam Therapeutics Inc
- Current
- 1M Ago
- 3M Ago
Analyst Forecast on Beam Therapeutics Inc
What analysts predicted
Upside of 84.62%
Beam Therapeutics Inc Technicals Summary
Sell
Neutral
Buy
Beam Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Beam Therapeutics Inc Vs Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Beam Therapeutics Inc | 19.24% | 10.03% | -8.61% | -66.13% | -65.72% |
 Regeneron Pharmaceuticals, Inc. | -19.29% | -22.98% | -6.09% | 16.5% | 106.01% |
 Biontech Se | 6.62% | 28.33% | 24.67% | -65.3% | 465.36% |
 Alnylam Pharmaceuticals, Inc. | -12.52% | 67.25% | 57.65% | 33.12% | 110.8% |
 Vertex Pharmaceuticals Incorporated | -3.08% | 3.32% | 31.85% | 151.49% | 110.78% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Beam Therapeutics Inc | NA | NA | NA | -4.72 | -0.18 | -0.09 | NA | 9.97 |
Regeneron Pharmaceuticals, Inc. | 18.25 | 18.25 | 1.1 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Beam Therapeutics Inc | Buy | $2.1B | -65.72% | NA | -41.07% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.1B | 106.01% | 18.25 | 33.61% |
Biontech Se | Buy | $27.1B | 465.36% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 110.8% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.1B | 110.78% | 32.84 | -4.51% |
Beam Therapeutics Inc Institutional Holdings
Farallon Capital Management, L.L.C.
9.91%Vanguard Group Inc
9.47%BlackRock Inc
9.22%ARK Investment Management LLC
7.89%ARCH VENTURE CORP
5.84%FMR Inc
5.09%
Corporate Announcements
Beam Therapeutics Inc Earnings
Beam Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information about Beam Therapeutics Inc
beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other
Organization | Beam Therapeutics Inc |
Employees | 472 |
CEO | Mr. John M. Evans M.B.A. |
Industry | Health Technology |
